Key Takeaway: At the 2023 World Congress on Gastrointestinal Cancers, Dr. Michael Pishvaian presented promising interim data from a phase 3 study on intra-arterial gemcitabine for patients with locally advanced pancreatic cancer. The findings suggest potential benefits of this treatment approach, highlighting its relevance in oncology.
Price reaction · baseline $1.85 (2023-08-14 close) · hit pre-market · 1 other RNXT headline(s) in the window, move may be shared
day 0 close · peak
-4.3%
Market Sentiment Analysis
POSITIVE FACTORS
Promising results from the phase 3 study.
Intra-arterial gemcitabine shows potential for treatment.
Presented at a significant medical congress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer
Full Press Release Details
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
View the entire article on Oncology Learning Network
Frequently Asked Questions
What was presented at the 2023 World Congress?
Dr. Michael Pishvaian presented data from a phase 3 study on intra-arterial gemcitabine.
What type of cancer was the study focused on?
The study focused on locally advanced pancreatic cancer.
Who shared the study findings?
The findings were shared by Michael Pishvaian, MD, PhD.
What is the treatment being evaluated?
The treatment being evaluated is intra-arterial gemcitabine.